Brief: Linc's Gesynta Pharma Reports Results From An Exploratory Clinical Study Of The Drug Candidate GS-248

Linc AB

08/09/2022 13:05

Sept 8 (Reuters) - Linc AB  LIC.ST :
    * GESYNTA PHARMA REPORTS RESULTS FROM AN EXPLORATORY
CLINICAL
STUDY OF THE DRUG CANDIDATE GS-248
    * GS-248 WAS WELL TOLERATED, SHOWED A GOOD SAFETY PROFILE
    * NO SIGNIFICANT EFFECT ON THE PATIENTS' SYMPTOMS WAS
ACHIEVED
    * COMPANY MAKES THE ASSESSMENT THAT THE DEVELOPMENT PROGRAM
FOR
GS-248 SHOULD CONTINUE IN OTHER DISEASE AREAS

Source text for Eikon:  ID:nMFN1Tzk9R 
Further company coverage:  LIC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))